# agilon health, inc. (AGL) Stock Analysis: Is a 57% Upside Worth the Risks?

- Link: https://www.directorstalkinterviews.com/agilon-health-inc-agl-stock-analysis-is-a-57-upside-worth-the-risks/4121243905
- Published: 2026-03-10T11:37:27+00:00
- Author: Madison Wilson

In the ever-evolving landscape of healthcare, agilon health, inc. (NYSE: AGL) offers
a unique value proposition. Based in Westerville, Ohio, agilon health specializes
in providing comprehensive healthcare solutions for seniors through primary care
physicians across the United States. Despite its innovative platform, the company
faces a challenging market environment, reflected in its current stock price of 
$0.5999 and a market capitalization of $248.88 million.

Investors are often drawn to the potential for substantial gains. agilon health 
presents a compelling case with a potential upside of 57.39%, according to analyst
ratings. However, this potential needs to be balanced against a slew of performance
and valuation metrics that merit close examination.

The company’s revenue growth stands at a modest 3.10%, a figure that suggests gradual
expansion. However, agilon health’s financial health reveals some red flags. The
company is currently operating at a loss, with a negative earnings per share (EPS)
of -0.98 and a concerning return on equity (ROE) of -135.64%. These figures highlight
both operational challenges and a need for strategic pivots to achieve profitability.

Adding to the complexity is agilon health’s forward price-to-earnings (P/E) ratio
of -3.36, indicating that the market anticipates continued earnings challenges. 
The absence of a trailing P/E and other critical valuation metrics such as PEG ratio
and price/book ratio further complicates a straightforward valuation assessment.

From a technical standpoint, agilon health’s stock is navigating turbulent waters.
The 50-day moving average of $0.70 and the 200-day moving average of $1.19 suggest
a bearish trend. The relative strength index (RSI) at 74.73 indicates that the stock
is nearing overbought territory, which could signal an impending price correction.

Despite these concerns, the analyst sentiment reveals a broad spectrum of opinions,
with 2 buy ratings, 13 hold ratings, and 2 sell ratings. The target price range 
spans from $0.25 to $2.00, with an average target of $0.94. This wide range underscores
the uncertainty surrounding agilon health’s future performance and its potential
to navigate current market conditions effectively.

For income-focused investors, it’s important to note that agilon health does not
currently offer dividends, reflecting a payout ratio of 0.00%. This aligns with 
the company’s focus on reinvesting capital to fuel growth and mitigate financial
losses.

In light of these factors, agilon health presents a high-risk, high-reward scenario.
The company operates in a growing sector with significant long-term potential. However,
the immediate financial and operational hurdles demand careful consideration. Individual
investors should weigh the potential upside against the inherent risks, aligning
their investment strategy with their risk tolerance and long-term financial goals.

Share on:
